Total Cholesterol | ||||
---|---|---|---|---|
Patients on Placebo, n (%) | ||||
Year 3 | Total | |||
Normal | Abnormal | |||
Baseline | Normal | 6 (16.7) | 3 (8.3) | 9 (25.0) |
Abnormal | 4 (11.1) | 23 (63.9) | 27 (75.0) | |
Total | 10 (27.8) | 26 (72.2) | 36 (100) | |
p=NS | ||||
Patients on CGS, n (%) | ||||
Year 3 | Total | |||
Normal | Abnormal | |||
Baseline | Normal | 12 (19.4) | 7 (11.3) | 19 (30.6) |
Abnormal | 9 (14.5) | 34 (54.8) | 43 (69.4) | |
Total | 21 (33.9) | 41 (66.1) | 62 (100) | |
p=NS | ||||
LDL Cholesterol | ||||
Patients on placebo, n (%) | ||||
Year 3 | Total | |||
Normal | Abnormal | |||
Baseline | Normal | 8 (22.2) | 4 (11.1) | 12 (33.3) |
Abnormal | 5 (13.9) | 19 (52.8) | 24 (66.7) | |
Total | 13 (36.1) | 23 (63.9) | 36 (100) | |
p=NS | ||||
Patients on CGS, n (%) | ||||
Year 3 | Total | |||
Normal | Abnormal | |||
Baseline | Normal | 7 (11.1) | 5 (7.9) | 12 (19.0) |
Abnormal | 9 (14.3) | 42 (66.7) | 51 (81.0) | |
Total | 16 (25.4) | 47 (74.6) | 63 (100) | |
p=NS |